Probiotics in Elderly Patients With Medical Conditions (Probiotics)
Evaluation of the Efficacy of Probiotics in Treating Constipation in Elderly Patients With Multiple Chronic Co-morbidities: a Randomized Control Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Background and aims:
Probiotics are known to have a beneficial effect on the management of constipation. Thus, the current study objective was to evaluate the impact of a microbial cell preparation (MCP) (Hexbio®; comprising Bifidobacterium and Lactobacillus strains) on stool frequency, consistency, and constipation-related symptoms in elderly patients with multiple chronic medical conditions.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Wilayah Persekutuan Kuala Lumpur
-
Kuala lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia, 56000
- Universiti Kebangsaan Malaysia Medical Faculty
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-clinical diagnosis of constipation
Exclusion Criteria:
- Parkinson's disease,
- spinal cord lesions
- post radiation strictures
- on calcium supplements of greater than 1,500 mg per day
- immune-deficiency
- critical illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
placebo were manufactured and supplied by B-Crobes Laboratory Sdn.
Bhd. as powder in identical sachets with active comparator and labelled as A
|
inactive ingredient
|
|
Active Comparator: Hexbio® MCP
The treatment sample is labelled as B.This is an orange-flavoured, granulated microbial cell preparation containing 30 billion colony forming units (cfu) of Lactobacilli and Bifidobacteria strains: Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium bifidum BCMC® 02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC® 02120.
The placebo sample was similar in appearance and taste, but contained no microbial cells.
|
active microbial cell preparation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
changes in stool output frequency
Time Frame: 7 days
|
numerical scale 0-100 used, 0= nil (worst), 100= good, medium score was used for data interpratation
|
7 days
|
|
changes in stool consistency
Time Frame: 7 days
|
The Bristol Stool scale was used, scale type 1 to 7, type 1 = hard stool and type 7=entirely liquid stool, medium score was used for data intepretation
|
7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
patients' perceptions of an improvement in their constipation-related symptoms 1
Time Frame: 7 days
|
straining: likert score of 0 to 10 was used, 0=no straining, 10= worst straining
|
7 days
|
|
patients' perceptions of an improvement in their constipation-related symptoms 2
Time Frame: 7 days
|
sensation of incomplete evacuation: likert score of 0 to 10 was used, 0= total incomplete evacuation, 10=complete evacuation
|
7 days
|
|
patients' perceptions of an improvement in their constipation-related symptoms 3
Time Frame: 7 days
|
sensation of ano-rectal obstruction/blockage: likert score of 0 to 10 was used, 0=complete obstruction, 10= complete relieved
|
7 days
|
|
patients' perceptions of an improvement in their constipation-related symptoms 4
Time Frame: 7 days
|
Need of manual evacuation to aid defeacation: likert score of 0 to 10 was used, 0=no evacuation needed, 10=total evacuation needed
|
7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: hayati Yaakup, MBBS, National University of Malaysia
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FF-2016-417)
- NMRR-19-1761-49477 (Registry Identifier: The National Medical Registry of Malaysia)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
NCT07386795Not yet recruitingChronic Constipation | Constipation - Functional | Fecal Microbiota Transplantation
-
NCT06836024Not yet recruitingConstipation | Constipation - Functional | Constipation Aggravated
-
NCT07388589Not yet recruitingConstipation | Diet Modification | Constipation-predominant Irritable Bowel Syndrome | Diet Therapy | Constipation - Functional | Constipation Chronic Idiopathic | Constipation, Signs and Symptoms, Digestive | Dietary Fiber | Dietary Fibers | Constipation Predominant Irritable Bowel Syndrome
-
NCT06349031Not yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional Constipation
-
NCT07387952RecruitingChronic Constipation | Constipation - Functional | Fecal Microbiota Transplantation (FMT)
-
NCT07039409Not yet recruitingConstipation | Constipation Drug Induced | Psychiatric Drug Induced Constipation
-
NCT01523184CompletedChronic Constipation | Functional Constipation
-
NCT07039448RecruitingConstipation | Constipation Drug Induced | Psychiatric Drug Induced Constipation
-
NCT02361749UnknownChronic Idiopathic Constipation | Functional Constipation
-
NCT04262752CompletedConstipation | Constipation Chronic Idiopathic | Constipation; Neurogenic
Clinical Trials on placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT06767540Not yet recruiting
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04693039Completed
-
NCT01610388Completed
-
NCT04388215UnknownHypertension | Dyslipidemias